("Biodexa" or the "Company") About Biodexa Pharmaceuticals PLC MTX110 is a solubilised formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity. Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be ...